Clinical experience with chemoradiotherapy comprising S-1 plus low-dose cisplatin in a patient with stage IV anal cancer

  • Nobuhiro Nitori
  • , Yutaro Kato
  • , Ayu Kato
  • , Tomoaki Deguchi
  • , Akihiro Okada
  • , Masayuki Kojima
  • , Junko Kuroda
  • , Tomohisa Kadomura
  • , Eisuke Kubota
  • , Nobuto Origuchi
  • , Masato Fujisaki
  • , Masaki Kitajima

Research output: Contribution to journalArticlepeer-review

Abstract

We report a case of anal cancer in a 58-year-old woman who complained of narrow, bloody stools and anal pain. Physical examination revealed anal stenosis associated with a circular mass arising in the anal canal. Histological examination of biopsy specimens confirmed a diagnosis of moderately differentiated squamous cell carcinoma. Enhanced computed tomography revealed anal cancer invading the levator ani and the vagina, with lymph-node, multiple hepatic, and pulmonary metastases. The patient received two cycle of chemoradiotherapy with S-1 plus low-dose cisplatin with rest for 4 weeks, leading to complete response of the primary lesion and a partial response of the metastatic lesions. Each cycle included oral S-1 (120 mg/body; day1-21), cisplatin (10 mg/body; day1-5, 8-12) and radiotherapy (2 Gy/day; day 1-5, 8-12, 15-19). Adverse effects of treatment were mild perineal skin erosion and mild appetite loss, but no hematologic toxicity. Although the patient died 16 months after first admission, chemoradiotherapy with S-1 plus cisplatin is potentially effective for the management of advanced anal cancer.

Original languageEnglish
Pages (from-to)3983-3989
Number of pages7
JournalAnticancer research
Volume31
Issue number11
Publication statusPublished - 11-2011
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Clinical experience with chemoradiotherapy comprising S-1 plus low-dose cisplatin in a patient with stage IV anal cancer'. Together they form a unique fingerprint.

Cite this